Summary
9.71 -0.22(-2.22%)05/17/2024
Vir Biotechnology Inc (VIR)
Vir Biotechnology Inc (VIR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.89 | 17.16 | 4.32 | 8.91 | 17.30 | -58.99 | 0.00 | -29.39 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 9.90 | |
| Open | 10.34 | |
| High | 10.46 | |
| Low | 9.86 | |
| Volume | 613,520 | |
| Change | -0.30 | |
| Change % | -2.89 | |
| Avg Volume (20 Days) | 742,916 | |
| Volume/Avg Volume (20 Days) Ratio | 0.83 | |
| 52 Week Range | 7.61 - 27.48 | |
| Price vs 52 Week High | -63.97% | |
| Price vs 52 Week Low | 30.09% | |
| Range | -4.26 | |
| Gap Up/Down | -0.20 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,324 | |
| EBIDTA | -126,076,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 77.14 | |
| Book Value | 6.6980 | |
| Earnings Per Share | -0.7960 | |
| EPS Estimate Current Quarter | 0.0200 | |
| EPS Estimate Next Quarter | -0.0100 | |
| EPS Estimate Current Year | 1.6100 | |
| EPS Estimate Next Year | 0.3800 | |
| Diluted EPS (TTM) | -0.7960 | |
| Revenues | ||
| Profit Marging | -0.3598 | |
| Operating Marging (TTM) | -0.6179 | |
| Return on asset (TTM) | -0.1020 | |
| Return on equity (TTM) | -0.1212 | |
| Revenue TTM | 284,401,984 | |
| Revenue per share TTM | 2.2050 | |
| Quarterly Revenue Growth (YOY) | 52.7430 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -196,511,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 14.0647 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 6.5121 | |
| Revenue Enterprise Value | 17.0149 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 130,880,000 | |
| Shares Float | 71,603,226 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 13.07 | |
| Institutions (%) | 73.41 | |
05/13 19:21 EST - prnewswire.com
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
DURHAM, N.C. and BEIJING, May 13, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designations for BRII-877 (tobevibart), an investigational broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) and BRII-835 (elebsiran), an investigational HBV-targeting small interfering ribonucleic acid (siRNA).
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
DURHAM, N.C. and BEIJING, May 13, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designations for BRII-877 (tobevibart), an investigational broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) and BRII-835 (elebsiran), an investigational HBV-targeting small interfering ribonucleic acid (siRNA).
05/07 11:01 EST - zacks.com
Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.7% in Vir Biotechnology (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.7% in Vir Biotechnology (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
05/03 00:35 EST - seekingalpha.com
Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Carrie Huang - Senior Vice President, Clinical Research and Interim Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Alec Stranahan - Bank of America Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright Rosa Chen - Leerink Partners Joseph Stringer - Needham & Company Eric Joseph - JP Morgan Michaels Ulz - Morgan Stanley Operator Hello.
Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Carrie Huang - Senior Vice President, Clinical Research and Interim Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Alec Stranahan - Bank of America Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright Rosa Chen - Leerink Partners Joseph Stringer - Needham & Company Eric Joseph - JP Morgan Michaels Ulz - Morgan Stanley Operator Hello.
05/02 19:06 EST - zacks.com
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.06 per share a year ago.
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.06 per share a year ago.
05/02 16:05 EST - businesswire.com
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. “We are excited to share important data from our Phase 2 chronic hepatitis delta SOLSTICE trial at the upcoming EASL congress. This milestone brings us closer to addressing the significant unmet medical need for the millions of people living with hepatitis delta,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief.
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. “We are excited to share important data from our Phase 2 chronic hepatitis delta SOLSTICE trial at the upcoming EASL congress. This milestone brings us closer to addressing the significant unmet medical need for the millions of people living with hepatitis delta,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief.
04/30 16:05 EST - businesswire.com
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About.
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About.
04/24 13:01 EST - zacks.com
What Makes Vir Biotechnology (VIR) a New Buy Stock
Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Vir Biotechnology (VIR) a New Buy Stock
Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
04/18 08:00 EST - businesswire.com
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”). If elected, each of Drs. Bischofberger and Farid will join the Board on such date. The nomination of the two new independent directors demonstrates Vir's commitment to ongoing Board refreshment.
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”). If elected, each of Drs. Bischofberger and Farid will join the Board on such date. The nomination of the two new independent directors demonstrates Vir's commitment to ongoing Board refreshment.
04/11 16:30 EST - businesswire.com
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of th.
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of th.
03/19 14:58 EST - investorplace.com
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.
03/13 11:07 EST - investorplace.com
Billionaire's Biotech Bets: 3 Stocks Dominating Bill Gates' Portfolio
Since Bill Gates left his position with Microsoft (NASDAQ: MSFT ) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest.
Billionaire's Biotech Bets: 3 Stocks Dominating Bill Gates' Portfolio
Since Bill Gates left his position with Microsoft (NASDAQ: MSFT ) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest.
02/27 23:56 EST - seekingalpha.com
Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Vir Biotechnology is developing treatments for Hepatitis B, Hepatitis Delta, HIV, and COVID, among others.
Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Vir Biotechnology is developing treatments for Hepatitis B, Hepatitis Delta, HIV, and COVID, among others.
02/26 06:55 EST - investorplace.com
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It's also fairly easy to identify such stocks using screener tools that can tease out such opportunities.
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It's also fairly easy to identify such stocks using screener tools that can tease out such opportunities.
02/23 10:56 EST - zacks.com
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade
The consensus price target hints at an 186.4% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade
The consensus price target hints at an 186.4% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
02/23 08:05 EST - businesswire.com
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR--Vir Biotechnology to participate in upcoming March investor healthcare conferences.
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR--Vir Biotechnology to participate in upcoming March investor healthcare conferences.
02/22 20:48 EST - seekingalpha.com
Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript
02/22 18:51 EST - zacks.com
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $0.76 per share a year ago.
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $0.76 per share a year ago.
02/22 16:05 EST - businesswire.com
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023. “Vir is poised to have a transformational year, with catalysts expected in the second and fourth quarters, which build off last year's clinical trial progress in our chronic hepatitis delta and B programs. We believe these data readouts, notably the SOLSTICE delta update in the second quarter, hold tr.
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023. “Vir is poised to have a transformational year, with catalysts expected in the second and fourth quarters, which build off last year's clinical trial progress in our chronic hepatitis delta and B programs. We believe these data readouts, notably the SOLSTICE delta update in the second quarter, hold tr.
02/01 16:05 EST - businesswire.com
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR--Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024.
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR--Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024.
01/31 13:16 EST - zacks.com
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.